What the human tests did and didn't answer
What can the CJC-1295 studies answer for you?
The CJC-1295 studies checked blood hormones, short-term harm, and how fast the drug left blood. They didn't prove a health gain. I'd take these facts to your doctor.
What is CJC-1295, in everyday words?
CJC-1295 is a peptide: a short man-made chain of amino acids your body uses to build proteins. It copies a message telling your growth gland to release hormone. Four changes slow its breakdown. In the early 2000s, ConjuChem made a long form that binds albumin, a protein in blood [01][02].
Staying longer in blood doesn't prove you'll feel better or gain health.
Which hormones changed after people got CJC-1295?
A receptor is a growth-gland cell's docking spot. The drug attaches there, and the gland releases bursts. Stage 1, the first people test, measured the rise. In stage 1, healthy adults got one skin shot in 2006. Growth hormone rose two- to ten-fold for at least six days. Insulin-like growth factor, a liver-made hormone that helps your tissue grow, rose 1.5- to 3-fold through days nine to eleven [01].
Researchers didn't ask how the adults felt. The result can't predict your day.
What do CJC-1295 DAC and CJC-1295 no DAC mean?
DAC stands for Drug Affinity Complex, the maker's name for the extra part on the long form. It attaches to albumin, a protein in your blood. Half the long form remained for a 5.8-8.1 day span [01][02]. The no DAC form acts fast. Modified growth-hormone-releasing factor is another name for your body's changed message. Half leaves in about 30 minutes [13].
You can't judge a time claim unless it names the form.
What does CJC-1295 half-life mean for the two forms?
Half-life tells you when half the drug is gone from your blood. In 2006, researchers estimated 5.8 to 8.1 days for the long form [01]. Half the short form leaves in about 30 minutes. With sermorelin, a related drug that gives your gland a similar message, half was gone in less than ten minutes [04][13]. Changes in the short form help it last longer.
You can't assume your body will match those group times.
When did each hormone rise after CJC-1295?
Stage 1, the early tests in people, found higher growth hormone within 24-48 hours after one skin shot. Insulin-like growth factor also rose during stage 1. In the stage 1 repeat-shot test, this liver-made hormone stayed high through the 28-day period [01]. Those blood changes aren't proof that you'd feel better. Unpublished stage 2 findings can't tell you what your body would do [18].
Which CJC-1295 side effects did people report most?
In stage 1, the first small human tests, and stage 2, the later test, people most often had sore skin near the needle, a brief flush, or a headache [01][18]. Some also had mild swelling from extra fluid. Higher growth hormone can make your kidneys keep more water and salt [06]. Long-term harm isn't known because the later work stopped before large tests [07].
Short studies can't settle what years of use might do to your body.
Can short CJC-1295 studies prove long-term safety?
Some records use stage 1/2 for a test that combines the first safety stage with an early check for benefit. Those records cover little time. The FDA hasn't approved the drug for medical use [20]. In a 2006 report, short human tests found no serious harm at the amounts studied. The largest one-time skin shot was 250 micrograms per kilogram of body weight [01]. Researchers didn't follow healthy adults or many people with other illnesses for years.
A quiet short study can't guarantee long-term safety for you.
Did people's testosterone rise after CJC-1295?
CJC-1295 works through the growth-hormone system [01]. In stage 1, no published CJC-1295 study found a useful rise in blood testosterone. The drug acts on the growth gland, not the glands that control sex hormones. Researchers didn't show a rise in your level. That doesn't prove it would stay the same for you.
How did CJC-1295 tell the gland to release hormone?
The drug attaches to a receptor, a docking spot on the outside of growth-gland cells [05][20]. The body's natural release message fits there too. Once either one attaches, the cells release stored growth hormone [05]. Your gland supplies the hormone; the drug doesn't bring hormone from elsewhere. Stage 1 blood tests found larger bursts from the body. The long form kept sending its message for days.
These cell steps explain the blood rise, not whether you'd feel better.
What does “CJC-1295 mechanism of action” mean?
The phrase means how CJC-1295 works. It copies your body's message to the growth gland. Four changes slow the drug's breakdown [02]. The long form binds albumin, a common blood protein, which keeps the drug in blood longer [02][12]. At a gland cell, the drug prompts stored growth hormone to leave [05]. Stage 1 blood tests found larger bursts.
That explains how the drug acts. It doesn't show that treatment would help you.
Which CJC-1295 amounts did human studies use?
In 2006, healthy adults got one skin shot containing 30, 60, 125, or 250 micrograms per kilogram [01]. A microgram is a tiny measure of weight. The person's weight set the total amount. Another group got 30-60 micrograms per kilogram weekly or every other week for 28-49 days. Stage 2, the later test, used 60-120 and 60-240 micrograms per kilogram for twelve weeks [18].
Those study amounts aren't a dose for you or a guide for your doctor.
What has the FDA said about CJC-1295?
No. The FDA has never approved CJC-1295 for medical use. ConjuChem, the company that made it, stopped human tests in 2006 before large late studies [07]. In December 2024, an FDA advice group weighed whether pharmacies could use CJC-1295 powder to make custom medicine for one patient. The group's review didn't support that use [20].
The decision doesn't make a vial approved or prove that it's safe for you or fits your body.
Why is the short form called modified GRF?
GRF stands for growth-hormone-releasing factor, your body's message telling the gland to release growth hormone. Papers call short-form CJC-1295 modified GRF because scientists changed four spots to slow its breakdown [02]. It can't attach to albumin. Half leaves blood in about 30 minutes, so studies used several shots daily [13].
When you read a time claim, don't confuse the short form with the long one.
Why isn't Ipamorelin, another hormone drug, the same as CJC-1295?
CJC-1295 copies one body message for your growth gland [02]. Ipamorelin is another drug that copies a different message [10]. Each attaches to a different receptor, or docking spot, on the cell. That means a result for one drug can't prove the other works or stays safe. A study in men tested both routes together [10]. Seeing both names still doesn't prove that using both would help you without harm.
The pair doesn't give your doctor enough human proof to predict your result.
What is the long form of CJC-1295 made from?
The drug is a chain of thirty amino acids, small pieces your body uses to build proteins. Four changes slow its breakdown. One extra amino acid holds an added part on the long form. It binds albumin, a common blood protein [02][12]. The short form can't bind, and its chain ends another way.
The drug's parts can't show whether it will help, harm, or fit your health.
Which company made CJC-1295, and what did it hope to do?
ConjuChem Inc., a drug company in Montreal, made CJC-1295 in the early 2000s. The long form was meant to attach to albumin, a protein carried in your blood [02][12]. The company hoped for a weekly skin shot for adults who made too little growth hormone. In 2005, researchers tested three forms in rats and rat cells. CJC-1295 caused the strongest growth hormone release [03].
Rat work can't show that you'd gain health or that your body would stay safe.
How long could blood tests find CJC-1295?
Labs found the long form in blood for about 14-21 days because albumin held it there. Albumin is a common blood protein. Its message at your growth gland lasted six to eight days per dose [01][12]. The short form didn't last for days. Its 30-minute half-life means half was gone by then [13].
A trace in blood can't predict how you'd feel.
Which CJC-1295 studies tested health, and which only found the drug?
Researchers checked blood hormones in healthy adults and planned to check body shape in adults with HIV. Animal work looked at muscle, bone, and fat [01][03][18]. Other labs made tests only to find the drug in blood or urine [08][09][19]. Those tests can show that it reached a sample. They can't show that your health would improve.
Finding the drug isn't the same as finding a benefit for you.
Can CJC-1295 make you hold extra water?
Your kidneys may hold extra water and salt when growth hormone is high [22]. Some CJC-1295 study volunteers had mild swelling [06][22]. In stage 3, the larger late tests, researchers studied tesamorelin, an approved drug that sends the gland a similar message. About 6% had swelling in an arm or leg. The rate was 2% after a placebo, a shot with no drug [06].
Those rates can't tell you your chance of swelling.
Why did CJC-1295 shot schedules differ by form?
Some records use stage 1/2 when a study joins safety and an early benefit check. Human studies used a weekly skin shot for the long form because it took days to leave blood [01][18]. Short-form studies used 1-3 shots each day because half left by the 30-minute mark [13]. Those times can't set your schedule or guide your doctor.
What three things did the CJC-1295 human tests check?
The human tests asked 3 questions: how hormones changed, how long the drug stayed, and what harm occurred [01]. Stage 1 was the first test with volunteers. Researchers measured insulin-like growth factor binding protein, which carries insulin-like growth factor in your blood. That check showed how your body's growth system responded. Stage 2, the later test, used scans to measure fat deep around the organs. Its main findings weren't published, so they can't guide your doctor or be compared with your health [18].
How many human CJC-1295 trials are on record?
Records show at least four stage 1 and stage 1/2 trials. The slash means the test joined safety and benefit checks. Three appear here: two rising-amount trials from 2006 and one stage 2 study in people with HIV and extra belly fat [01][18]. Another trial has no published result. Work stopped in 2006.
You can't learn what the drug would do from any large finished trial.
Why did human testing of CJC-1295 end?
ConjuChem, the company that made CJC-1295, stopped its stage 2 study in 2006 after one person died from a heart attack. The study doctor blamed heart disease already present, not CJC-1295 [07]. The company then ended work on its group of long-form drugs, which included this one. No outside report tied the drug to the death, but the stage 2 study didn't restart [07].
The public record can't tell you for certain what caused the death.
Can CJC-1295 studies rule out cancer years later?
Research hasn't shown that CJC-1295 itself caused cancer [21]. No long study can clear it either. The concern is insulin-like growth factor, a blood hormone that tells many kinds of tissue to grow. Stage 1 was too short to settle cancer risk. The stage 1 results didn't follow people for years, and the stage 1 record can't rule out late harm. Other growth-hormone drugs raise the same concern [21].
Your lifetime risk isn't known. A lack of reports isn't proof of safety.